drugset / Trial / NCT02698657

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

NCT02698657 ↗

Phase 1 Completed 30 enrolled Astellas Pharma Global Development, Inc.
RandomizedSingle-groupDouble-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of multiple ascending intravenous doses of ASP5094 in male and female subjects with rheumatoid arthritis (RA) on methotrexate (MTX).

Timeline

Start
2016-02-23
Primary completion
2017-09-07
Completion
2017-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ASP5094 Monoclonal antibody — Intravenous

Indications